Nanosphere Health Sciences Inc
NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing biologically active compounds in the United States and Canada. It offers NanoSphere Delivery System, a platform using nanotechnology in the biodelivery of supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, animal health, and other industries. NanoSphere Health Sciences … Read more
Nanosphere Health Sciences Inc (NSHSF) - Net Assets
Latest net assets as of September 2025: $-1.37 Million USD
Based on the latest financial reports, Nanosphere Health Sciences Inc (NSHSF) has net assets worth $-1.37 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.23K) and total liabilities ($1.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.37 Million |
| % of Total Assets | -8446.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 664.45 |
Nanosphere Health Sciences Inc - Net Assets Trend (2005–2024)
This chart illustrates how Nanosphere Health Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanosphere Health Sciences Inc (2005–2024)
The table below shows the annual net assets of Nanosphere Health Sciences Inc from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.22 Million | +21.80% |
| 2023-12-31 | $-1.56 Million | -18.64% |
| 2022-12-31 | $-1.31 Million | -21.98% |
| 2021-12-31 | $-1.08 Million | +26.02% |
| 2020-12-31 | $-1.45 Million | -58.11% |
| 2019-12-31 | $-919.49K | -209.74% |
| 2018-12-31 | $837.88K | -77.24% |
| 2017-12-31 | $3.68 Million | +367.59% |
| 2016-12-31 | $787.23K | +988.81% |
| 2015-12-31 | $-88.57K | +34.31% |
| 2014-12-31 | $-134.84K | +64.17% |
| 2013-12-31 | $-376.36K | -105.90% |
| 2012-12-31 | $6.38 Million | +8.87% |
| 2011-12-31 | $5.86 Million | +19.09% |
| 2010-12-31 | $4.92 Million | +904.93% |
| 2009-12-31 | $489.35K | +277.75% |
| 2008-12-31 | $129.54K | -97.97% |
| 2007-12-31 | $6.38 Million | +2170.94% |
| 2006-12-31 | $281.06K | -10.30% |
| 2005-12-31 | $313.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanosphere Health Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2125813706.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.76 Million | % |
| Other Comprehensive Income | $1.30 Million | % |
| Total Equity | $-1.22 Million | 100.00% |
Nanosphere Health Sciences Inc Competitors by Market Cap
The table below lists competitors of Nanosphere Health Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Tymbal Resources Ltd.
V:NTB
|
$395.98K |
|
ValueInvest Global Akk KL
CO:VAIGAKA
|
$396.32K |
|
COGNEX - Dusseldorf Stock Exchang
DU:CGZ
|
$396.76K |
|
The Shyft Group Inc
F:SP8
|
$396.81K |
|
Marine Bancorp of Florida Inc
PINK:MBOF
|
$395.40K |
|
Multifiling Mitra Indonesia
JK:MFMI
|
$395.30K |
|
BEKAERT - Dusseldorf Stock Exchang
DU:BK8N
|
$395.27K |
|
HPE-P-C
PINK:HPE-P-C
|
$395.19K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanosphere Health Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,556,461 to -1,217,214, a change of 339,247.
- Net income of 263 contributed positively to equity growth.
- Other comprehensive income increased equity by 75,915.
- Other factors increased equity by 263,069.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $263.33 | +0.02% |
| Other Comprehensive Income | $75.92K | +6.24% |
| Other Changes | $263.07K | +21.61% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nanosphere Health Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $3775.24 | $0.06 | x |
| 2006-12-31 | $3386.28 | $0.06 | x |
| 2007-12-31 | $2804.36 | $0.06 | x |
| 2008-12-31 | $55.31 | $0.06 | x |
| 2009-12-31 | $201.71 | $0.06 | x |
| 2010-12-31 | $343.77 | $0.06 | x |
| 2011-12-31 | $156.19 | $0.06 | x |
| 2012-12-31 | $135.29 | $0.06 | x |
| 2013-12-31 | $-5.07 | $0.06 | x |
| 2014-12-31 | $-0.63 | $0.06 | x |
| 2015-12-31 | $-0.17 | $0.06 | x |
| 2016-12-31 | $0.66 | $0.06 | x |
| 2017-12-31 | $6.69 | $0.06 | x |
| 2018-12-31 | $0.17 | $0.06 | x |
| 2019-12-31 | $-0.17 | $0.06 | x |
| 2020-12-31 | $-0.27 | $0.06 | x |
| 2021-12-31 | $-0.16 | $0.06 | x |
| 2022-12-31 | $-0.13 | $0.06 | x |
| 2023-12-31 | $-0.15 | $0.06 | x |
| 2024-12-31 | $-0.12 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanosphere Health Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-254.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -8.10% | -729.21% | 0.01x | 1.02x | $-56.70K |
| 2006 | -11.09% | -325.05% | 0.03x | 1.04x | $-59.26K |
| 2007 | -15.12% | 0.00% | 0.00x | 1.22x | $-1.60 Million |
| 2008 | -3990.95% | 0.00% | 0.00x | 2.51x | $-5.18 Million |
| 2009 | 33.16% | 0.00% | 0.00x | 1.03x | $113.34K |
| 2010 | -4.00% | 0.00% | 0.00x | 1.02x | $-688.48K |
| 2011 | -154.58% | 0.00% | 0.00x | 1.05x | $-9.64 Million |
| 2012 | -58.52% | 0.00% | 0.00x | 1.08x | $-4.37 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.41 Million |
| 2014 | 0.00% | -3519.87% | 0.07x | 0.00x | $-206.16K |
| 2015 | 0.00% | -871.95% | 0.08x | 0.00x | $-124.76K |
| 2016 | -78.08% | -1491.94% | 0.04x | 1.30x | $-693.40K |
| 2017 | -269.21% | -20672.19% | 0.01x | 1.05x | $-10.28 Million |
| 2018 | -538.86% | -11918.90% | 0.03x | 1.57x | $-4.60 Million |
| 2019 | 0.00% | -1591.04% | 0.65x | 0.00x | $-3.38 Million |
| 2020 | 0.00% | 0.00% | -0.93x | 0.00x | $-445.84K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-248.72K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-150.56K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-72.35K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $121.98K |
Industry Comparison
This section compares Nanosphere Health Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanosphere Health Sciences Inc (NSHSF) | $-1.37 Million | -8.10% | N/A | $395.89K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |